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The proteasome is a large, multiple subunit complex that is capable of degrading most intracellular proteins. Polymorphisms in
proteasome subunits are associated with cardiovascular diseases, diabetes, neurological diseases, and cancer. One polymorphism
in the proteasome gene PSMA6 (−8C/G) is associated with three different diseases: type 2 diabetes, myocardial infarction,
and coronary artery disease. One type of proteasome, the immunoproteasome, which contains inducible catalytic subunits, is
adapted to generate peptides for antigen presentation. It has recently been shown that mutations and polymorphisms in the
immunoproteasome catalytic subunit PSMB8 are associated with several inflammatory and autoinflammatory diseases including
Nakajo-Nishimura syndrome, CANDLE syndrome, and intestinalM. tuberculosis infection. This comprehensive review describes
the disease-related polymorphisms in proteasome genes associated with human diseases and the physiological modulation of
proteasome function by these polymorphisms. Given the large number of subunits and the central importance of the proteasome in
human physiology as well as the fast pace of detection of proteasome polymorphisms associatedwith human diseases, it is likely that
other polymorphisms in proteasome genes associated with diseases will be detected in the near future. While disease-associated
polymorphisms are now readily discovered, the challenge will be to use this genetic information for clinical benefit.
1. Introduction
Over the last decade, significant improvements have been
made in genotyping efficiency, sequencing technology, and
statistical methodology, providing researchers with better
opportunities to define the role of sequence variation in the
development of human diseases [1–3]. Many human diseases
are now known to have a genetic component. All humans
start their lives with germ-line mutations inherited from
their parents. However, the human genetic code is constantly
subjected tomutations which can happen during cell division
or after exposure to environmental factors such as UV
radiation, chemicals, or viruses.Thesemutations can result in
proteins with altered functions, malformed proteins, or even
missing proteins. Some of these changes that occur due to
a particular mutation have no effect on biological function
(silent mutations), some may be beneficial, and some may
lead to disease. These genetic variations are important for
genetic diversity within the population.
Genome-wide association (GWA) studies have identi-
fied alleles related to complex disorders; however some of
these alleles seem to be associated with the disease only
in certain populations. Most investigations use dense maps
of single-nucleotide polymorphisms (SNPs) as well as the
haplotypes derived from these polymorphisms. Determining
the underlying causal relationship between SNP or haplo-
type and disease is currently a major challenge. Polymor-
phisms (termed “alleles”) occur more often (frequency of
1% or greater) in the general population than mutations
[4, 5]. Single-nucleotide polymorphisms (SNPs) are the most
common type of polymorphism and account for 90% of
human DNA polymorphisms. Most SNPs have two alleles
which are designated “major” and “minor” based on their
observed frequency in the general population. At each SNP,
several genotypes are possible because chromosomes are both
maternal and paternal in origin: homozygous for the major
allele, heterozygous, or homozygous for the minor allele. It is
estimated that more than 10 million SNPs occur in our whole
genome (once every 100∼300 bases) [6]. Because of the large
number of SNPs in the whole genome, investigation of all the
SNPs for a large number of individuals is time-consuming
and costly. Whole genome sequencing for large sample
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numbers is also not desirable becausemany SNPs are rare and
occur only once (“singletons”) or twice (“doubletons”) in the
analyzed samples.
The haplotype refers to an individual collection of short
tandem repeat allele mutations at adjacent locations (loci)
that are inherited together. Genome scan approaches to
find regions associated with diseases are now much more
efficient due to efforts such as the HapMap [6]. The HapMap
contains maps of haplotype blocks and their SNPs, allowing
users to select a group of SNPs to investigate a possible
association between known genomic regions and the disease
being studied. Smaller research labs are now able to analyze
multiple genes belonging to the same pathway instead of
analyzing a single polymorphism on a single gene. These
advances have led to the discovery of new polymorphisms on
proteasome genes that are linked to major human diseases.
1.1. The Ubiquitin-Proteasome System (UPS). The UPS is
the major pathway for degrading intracellular proteins. The
number of cellular processes that the UPS system is involved
in is impressive and includes cell cycle regulation, cellular
differentiation, removal of abnormal and misfolded intracel-
lular proteins, and generation of antigenic peptides [7–10].
The first step in UPS-mediated protein degradation involves
ubiquitination, which acts as a signal for degradation and
is carried out by a series of enzyme-mediated reactions
involving at least three types of enzymes, E1, E2, and E3
(Figure 1). The ubiquitin-activating enzyme (E1) generates
activated ubiquitin (Ub) via an ATP-dependent mechanism.
Activated Ub is transferred to the ubiquitin-conjugating
enzymes (E2), which, together with ubiquitin protein ligases
(E3), ligates Ub to lysine residues on protein substrates [11].
This process of ubiquitination occursmultiple times resulting
in ubiquitinated substrates which are recognized by the
proteasome or proteasome associated proteins. Once bound
to the proteasome, the polyubiquitin tag on the substrate
is removed by deubiquitinases which allows the Ub to be
recycled in the cell. The deubiquitinated substrate is then
unfolded and translocated into the 20S core by the 19S
regulatory particle. Once inside the core, the substrate is
degraded by the proteolytic enzymes of the 20S proteasome.
The proteasome contains three proteolytic activities: caspase-
like (𝛽1i), trypsin-like (𝛽2i), and chymotrypsin-like (𝛽5i)
activity.
The importance of the proteasome in cellular functions
is exemplified by experimental evidence which suggests that
the proteolytic capacity of the proteasome in certain tissues
declines with age and that this decline in proteasome activity
is related to the lifespan of the organism [12–16]. In contrast,
long-lived naked mole rats and centenarians show elevated
proteasome levels and activity [15, 16]. Aging cells have
increased levels of damaged proteins, possibly increasing
the load on the proteasome [17]. This proposed imbalance
between proteasome activity and proteasome substrate load
has been suggested to be responsible for the buildup of
protein aggregates in aged cells. The impact of proteasome
proteolytic capacity on the replicative lifespan in Saccha-
romyces cerevisiaewas investigated using a genetic system that
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Figure 1: Schematic diagram of the ubiquitin-proteasome system.
TheUPS involves at least three enzymes (E1, E2, andE3) that catalyze
the addition of ubiquitin to lysine residues on the substrate protein.
Polyubiquitinated substrates are then recognized by the proteasome
or proteasome associating protein, and the ubiquitin removed by
deubiquitinases and the substrate unfolded and translocated in the
20S core for proteolysis.
allowed the abundance of UPS components to be manipu-
lated at the transcriptional level [18]. Increasing the levels of
the UPS-related transcription factor Rpn4 upregulates UPS
components and enhances replicative lifespan and resistance
to proteotoxic stress. This effect of increased proteasome
capacity on lifespan is independent of the proteotoxic stress
response [18].
In a yeast model for neurodegenerative diseases, elevated
proteasome capacity results in improved clearance of toxic
Huntington fragments, suggesting that lifespan extension
may be related to elimination of damaged proteins in old cells
[18]. Overexpression of the proteasomal deubiquitinating
subunit Rpn11 extends lifespan in flies [19]. In C. elegans the
downregulation of proteasome regulatory particle subunits
leads to a substantial shortening of lifespan [20].
1.2. Proteasome Components. The proteasome is a multicat-
alytic enzyme which is highly conserved. The predominant
intracellular form is composed of two large complexes, the
20S and 19S complexes (Figure 2) [21–23]. Proteasomes are
found in archaebacteria as well as the nucleus and cytoplasm
of all eukaryotic organisms. The proteasome complex is
essential for cellular processes, as removal of any proteasome
gene is lethal in eukaryotes [24, 25]. The 20S proteasome,
or core particle, contains the proteolytic sites responsible
for protein degradation. The 20S proteasome is a 28-subunit
barrel-like structure of four rings of subunits (two 𝛼 and two
𝛽 rings, arranged 𝛼𝛽𝛽𝛼), with each ring containing seven
subunits. Each 𝛼 and 𝛽 subunit occurs in duplicate and three
of the 𝛽 subunits have proteolytic capabilities: 𝛽1 (encoded
by PSMB6 gene), with caspase-like proteolytic activity; 𝛽2
(PSMB7), with trypsin-like activity; and 𝛽5 (PSMB5), with
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Figure 2: Schematic diagram of the 26S proteasome. The 26S proteasome is composed of the core 20S proteasome and the 19S proteasome
complex.
chymotrypsin-like activity. The gene and protein names of
the components of the proteasome are shown in Table 1.
The 19S proteasome complex, or regulatory complex, is
important in mediating substrate recognition, processing,
and transporting substrates into the catalytic chamber of the
20S core [26]. Modulation of the 20S and 26S proteasomes by
posttranslational modifications has been shown to affect pro-
teasome activity [27]. The 19S is structurally more complex
than the 20S, with six different ATPases that unfold globular
proteins, non-ATPase regulatory subunits that bind polyu-
biquitin chains, and non-ATPase regulatory subunits that
cleave ubiquitin moieties off of polyubiquitinated proteins.
TheATP-dependent 19S regulatory complexes are involved in
unfolding and translocating polyubiquitinated substrates into
the interior of the 20S complex. Once inside the 20S core sub-
strates are degraded into oligopeptides.WhileATPhydrolysis
is not needed to cleave the substrate peptide bonds, ATP
is needed for substrate unfolding and translocation into the
proteasome’s 20S core chamber. The 19S proteasome can be
replaced by other proteasome activator complexes (also called
11S, encoded by PSME genes), or PA200 (PSME4) [28–30].
PI31 (PSMF1) inhibits the activation of the 20S proteasome
by 19S and 11S and inhibits hydrolysis of protein and peptide
substrates by the 20S proteasome [31, 32]. Intracellularly,
multiple forms of the proteasomewith different combinations
of activators coexist (Figure 3). These different forms have
different proteolytic activities and functions and are likely to
be an important contributing factor in diseases.
Two other 20S proteasome genes, PSMA8 and PSMB11
(codes for 𝛽5t), which occur in specific tissues, were recently
reported but are not currently known to be associated
with any diseases [33, 34]. In mammalian testis, most
proteasomes contain a spermatid/sperm-specific 𝛼 subunit
PSMA8 and the PA200 activator [33].Thesemammalian testis
proteasomes, called spermatoproteasomes, are important
for the polyubiquitin-independent degradation of histones.
Another catalytic proteasome subunit, 𝛽5t, was found to
be expressed exclusively in cortical thymic epithelial cells
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Figure 3: Schematic diagram of different forms of the proteasome.
Intracellular proteasome exists in different forms. The 26S pro-
teasome can exist with one or two 19S caps, immunoproteasomes
containing one or two 11S caps, proteasomes containing the 20S
proteasome with one or two PA200 caps (in the nucleus only), and
hybrid proteasomes which contain different combinations of 20S
and activators.
[34]. The replacement of 𝛽5 or 𝛽5i with 𝛽5t selectively
reduces chymotrypsin-like activity of the proteasome [34].
The thymoproteasome (proteasome with 𝛽5t) is important
for development of CD8(+) T cells in the thymus, as it plays
a key role in generating the MHC class I-restricted CD8(+) T
cell repertoire during thymic selection [34, 35].
2. 20S Proteasome Mutations and
Polymorphisms
While allPSMA andPSMB genes have known genemutations
[38], only a few 20S proteasome genes have detected poly-
morphisms that are associatedwith disease. Table 2 shows the
polymorphisms in proteasome genes that are associated with
diseases. Alignment of human PSMA (Figure 4) and human
PSMB (Figure 5) protein sequences shows that PSMA and
PSMB proteins have some homology with each other. Phylo-
genic analyses ofPSMA andPSMB protein subunits show that
all subunits are evolutionarily related to each other (Figure 6).
Current evidence suggests that two constitutive 20S genes,
PSMA6 and PSMA7, have polymorphisms associated with
human diseases.
2.1. PSMA6. The proteasome gene, PSMA6, codes for a 246
residue protein called 𝛼1. This protein is structurally impor-
tant in forming the outer 𝛼 rings of the 20S core proteasome.
The 𝛼1 protein function is also likely to be modulated by
posttranslational modifications including phosphorylation,
glycosylation, and lysine acetylation [60, 84]. In humans,
PSMA6 is most closely related to PSMA4 and PSMA2
(Figure 6). The location of the PSMA6 gene occurs in a
region containingmicrosatellites that have been implicated in
coronary artery disease (CAD) [85], type 2 diabetes mellitus
(T2DM) [86], and Grave’s disease [87].
2.1.1. Coronary Artery Disease. No association between two
SNPs (rs1048990 and rs12878371) in the PSMA6 gene, as
well as two SNPs in the KIAA0391 gene and one SNP
downstream of both genes, with CAD in a Saudi population
(1071 patients and 929 controls) was detected [85]. These two
genes,KIAA0391 andPSMA6, which have both been reported
to predispose individuals to CAD, form an evolutionarily
conserved cluster in the chromosomal region 14q13.2. Inter-
estingly, two haplotypes in the chromosomal region (five
SNPs in a 100 kb region of chromosome 14) encompassing
KIAA0391 and PSMA6 genes, 1A-2G-3C-4A-5A and 1A-2G-
3G-4A-5A, show increased risk of both CAD andmyocardial
infarction (MI), while another haplotype, 1T-2G-3C-4G-5A,
showed decreased risk of CAD and MI [85]. These latter
results suggest that disease risk factor determination may be
improved by investigating haplotypes instead of SNPs. Other
recent experimental data suggest that haplotypes are more
predictive than individual SNPs at determining risk factors
for complex diseases [90].
CAD is a complex disease, and several molecular path-
ways as well as loci and candidate genes that affect the
susceptibility to CAD have been suggested to be involved.
A functional sequence variation, −8C/G, in PSMA6 was
found to increase susceptibility to CAD [72]. 713 Caucasian
ischemic stroke patients (708 controls) and 166 African
American ischemic stroke patients (117 controls) were inves-
tigated using odds ratios (ORs) from multivariable logistic
regression models for twenty SNPs previously shown to be
associated with MI or CAD [72].The PSMA6 −8C > G (SNP
rs1048990) was found to have a protective association with
ischemic stroke in both Caucasians and African Americans
(i.e., decreased risk of ischemic stroke). Investigation of
1330 cases and 2554 controls from Japanese and Korean
populations for PSMA6 genotypes showed no evidence of the
association with either population [43]. An investigation of
6946MI patients and 2720 unrelated controls showed that the
homozygous GG genotype for the −8C > G polymorphism
was less frequent in the UK population (2.1%) than in the
Japanese population (8.9%) [91]. No association between the
PSMA6 polymorphism and MI was found in the British
population. Another genetic association study on PSMA6
−8C/Gusing 210North IndianCADpatients and 232 controls
did not shown any association between the PSMA6 variant
and CAD [92].
2.1.2. Myocardial Infarction. In a case-control association
study of 1884 MI Chinese patients and 2643 unrelated
controls, genotyping of the PSMA6 −8C > G polymorphism
showed that this SNP was associated with MI [73]. No
relationship between PSMA6 −8C > Gand sex, age, or other
conventional cardiovascular risk factors was detected. A
recent meta-analysis of 15,991 cases and 16,784 controls from
ten case-control studies suggest that the −8C/G sequence
variation is a risk factor for increased CAD susceptibility,
but the association between the sequence variation and CAD
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Table 1: Names and characteristics of human proteasome genes.
Gene
name
Protein
name Other names
Chromosome
location
Sequence
length MW (Da)
First
methionine
removed
Polymorphisms Reference
20S subunits
PSMA1 𝛼6
C2, Pro-𝛼5, 𝛼6 sc, nu,
Pros30, p30k, Pre5,
HC2, PSC2
11p15.1 263 29556 No rs17850016(G37V) [36, 37]
PSMA2 𝛼2
C3, Pro-𝛼2, 𝛼2 sc,
Pre8, Prs4, Y7, HC3,
PSC3, Lmpc3
7p14.1 233 25767 Yes (L110V) [38, 39]
PSMA3 𝛼7
C8, Pro-𝛼7, 𝛼7 sc,
Pre10, Prs1, C1, Prc1,
HC8, PSC8
14q23 254 28302 Yes [40]
PSMA4 𝛼3
C9, Pro-𝛼4, 𝛼3 sc,
Pre9, Prs5, Y13, HC9,
PSC9
15q25.1 261 29484 No [41]
PSMA5 𝛼5 Zeta, Pro-𝛼1, 𝛼5 sc,Pip2, Doa5, [Pup2] 1p13 241 26411 No [42]
PSMA6 𝛼1
Iota, Pro-𝛼6, 𝛼1 sc,
Pros27, pre27k, C7,
Prs2, Y8, Scl1
14q13 246 27399 No
rs1048990
(-8C-G),
rs15434 (A233S)
[37, 43, 44]
PSMA7 𝛼4 C6, Pro-𝛼3, 𝛼4 sc,XAPC-7, Pre6 20q13.33 248 27887 No 335C-A (A112D) [38, 45]
PSMA8 — PSMA7L 18q11.2 256 28530 No [46]
PSMB1 𝛽6 C5, gamma, Psc5,Pre7, Prs3, Pts1 6q27 241 26489 No
rs12717 (P11A),
rs10541 (I208N) [36, 47]
PSMB2 𝛽4 C7, Pre1, C11, C7-I,HC7-I 1p34.2 201 22836 No [48]
PSMB3 𝛽3 C10, theta, Pup3,C10-II 17q12 204 22818 Yes rs4907 (M34L) [48, 49]
PSMB4 𝛽7
N3, beta, Pros26,
HsN3, Pre4, Rn3,
Lmp3
1q21 264/219∗ 29204/24392∗ No
rs1804241
(M95I), rs4603
(I234T)
[46, 48–51]
PSMB5 𝛽5 X, epsilon, LmpX,MB1, Pre2, Doa3, Prg1 14q11.2 263/204
∗ 28480/22458∗ No rs11543947(R24C) [44, 48, 52]
PSMB6 𝛽1 Y, delta, LmpY, Pre3,Lmp19 17p13 239/205
∗ 25358/21904∗ Yes rs2304974(P107A) [44, 52]
PSMB7 𝛽2 Z, alpha, Pup1,Mmc14 9q34.11-q34.12 277/234
∗ 29965/25295∗ No rs4574 (V39A) [36, 53]
PSMB8 𝛽5𝑖 Lmp7, Psmb5i,Ring10, Y2, C13, Mc13 6p21.3 276/204
∗ 30354/22660∗ No
rs114772012
(G8R), (PGH30-
32RPD),
rs2071543
(Q49K),
rs17220206
(T74S), (T75M),
(G201V)
[46, 54–
57]
PSMB9 𝛽1𝑖 Lmp2, Psmb6i,Ring12 6p21.3 219/199
∗ 23264/21276∗ No
rs35100697
(G9E), rs241419
(V32I), rs17587
(R60H),
rs17213861
(R173C)
[58, 59]
PSMB10 𝛽2𝑖 MECL-1, Lmp10 16q22.1 273/234∗ 28936/24648∗ No [60]
PSMB11 𝛽5𝑡 beta5i-like, beta5t 14q11.2 300/251∗ 32530/27232∗ No rs34457782(G49S) [34]
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Table 1: Continued.
Gene
name
Protein
name Other names
Chromosome
location
Sequence
length MW (Da)
First
methionine
removed
Polymorphisms Reference
19S proteasome
PSMC1 Rpt2 S4, Yhs4, Yta5, P26s4 14q32.11 440 49185 Yes [38]
PSMC2 Rpt1 S7, Mss1, Yta3,Cim5, Nbla10058 7q22.1-q22.3 432 48503 Yes [61]
PSMC3 Rpt5 S6a, S6󸀠, p50, Tbp1,Yta1, Sata 11p11.2 439 49204 No [61]
PSMC4 Rpt3
S6b, S6, Mip224,
Tbp7, Yta2, Ynt1,
Cip21
19q13.11-q13.13 418 47336 No [61]
PSMC5 Rpt6
S8, p45, Trip1, Sug1,
Cim3, Crl3, Tbpy,
Tby1
17q23.3 405 45495 Yes
(R60Q),
rs11543211
(R258W)
[39, 44]
PSMC6 Rpt4
S10b, p42, Sug2,
Prs10, Pcs1, Crl13,
CADP44, P44
14q22.1 389 44173 No [38]
PSMD1 Rpn2 S1, p112, Sen3 2q37.1 953 105836 No [60]
PSMD2 Rpn1
S2, p97, Trap2, Hrd2,
Nas1, Rpd1, Protein
55.11
3q27.1 908 100200 No
rs11545172
(A176T),
rs11545169
(E313D),
rs17856236
(N724Y)
[44, 61]
PSMD3 Rpn3 S3, p58, Sun2, P91a,Tstap91a 17q21.1 534 60978 No [60]
PSMD4 Rpn10 S5a, ASF1, Mcb1, Sun1 1q21.3 377 40737 No [61]
PSMD5 — S5b, KIAA0072 9q34.11 503 56065 Yes
rs2297575
(E21G),
rs17282618
(L72H)
[60, 61]
PSMD6 Rpn7
S10a, SGA-113M,
p44S10, p42A,
PFAAP4, KIAA0107
3p21.1 389 45531 No [60]
PSMD7 Rpn8 S12, p40, Mov34L 16q23-q24 324 37025 No [62]
PSMD8 Rpn12 S14, p31, Nin1 19q13.2 350 39612 No [60]
PSMD9 — S15, p27 12q24.31-q24.32 223 24682 No
rs2230681
(V17A),
rs2291116 (T74I),
rs1177573
(R134W),
rs1177573
(E197G)
[50, 63–65]
PSMD10 Gank-yrin p28, p28(GANK) Xq22.3 226 24428 No [38]
PSMD11 Rpn6 S9, p44.5, Nas4 17q11.2 421 47333 Yes [38]
PSMD12 Rpn5 p55, Nas5 17q24.3 455 52773 Yes rs2230680(V358A) [60]
PSMD13 Rpn9 S11, p40.5, Les1, Nas7 11p15.5 376 42945 No
rs1045288
(N13S),
rs28927679
(S150L),
rs1794108
(G204E),
rs1794109
(L205F)
[36, 66–
68]
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Table 1: Continued.
Gene
name
Protein
name Other names
Chromosome
location
Sequence
length MW (Da)
First
methionine
removed
Polymorphisms Reference
PSMD14 Rpn11
Poh1, Mpr1, Mad1,
Pad1,
PAD1 homolog 1,
2q24.2 310 34577 No [38]
Proteasome activators
PSME1 PA28𝛼 PA28A, IFI5111, 1SREG-alpha 14q11.2 249 28723 No
rs1803830
(S55N), rs14930
(T244K)
[48, 52]
PSME2 PA28𝛽 PA28B, 1S REG-beta 14q12 238 27270 Yes rs7146672(H89P) [48, 60, 69]
PSME3 PA28𝛾 PA28G 17q21.31 253 29375 Yes [60, 70]
PSME4 PA200 KIAA0077, 1SREG-gamma 2p16.2 1843 211334 No
rs2302878
(I872V),
rs805408
(S1371T),
rs35903236
(T1825A)
[38, 44]
Proteasome inhibitor
PSMF1 PI31 20p13 271 29817 No
rs1803415
(F36C),
rs2235587
(H176R)
[60, 71]
∗Mature form of protein after propeptide is removed. When the first residue (methionine) of some proteins is removed, the molecular weights and sequence
length given represent the mature forms of the proteasome subunit with the methionine removed.
Table 2: Polymorphisms in proteasome genes associated with human diseases.
Gene Polymorphism Amino acidchange Disease References
20S subunits
PSMA6 −8C>G (rs1048990) —
Myocardial infarction [60, 72, 73]
Type 2 diabetes [74, 75]
Ischemic stroke [72]
Coronary artery disease [60]
PSMA7 335C>A A112D Intellectual disability [45]
19S subunits
PSMD3 SNPs rs4065321 and rs709592 — Diabetes [76]
PSMD7 SNP, rs17336700 in intron 3 — Ankylosing spondylitis [18]
Immunoproteasome subunits
PSMB8
c.224C>T T75M JMP syndrome [54]
G210V Nakajo-Nishimura syndrome [57]
c.224C>T, c.405C>A T75M CANDLE syndrome [77]
Q145K M. tuberculosis infection [78]
LMP-K/Q — Cancer [79]
LMP-Q/Q — Ankylosing spondylitis [80]
G/T-37360 — Type 1 diabetes mellitus [81]
PSMB9 HLA-B27 — Graves’ disease [82]
179G>A R60H Ankylosing spondylitis [83]
Table shows only disease-associated polymorphisms for which the SNP or amino acid change is known.
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1 58 P28066 PSMA5
1 53 O14818 PSMA7
1 55 Q8TAA3 PSMA8
1 60 P60900 PSMA6
1 56 P25787 PSMA2
1 55 P25789 PSMA4
1 58 P25788 PSMA3
1 56 P25786 PSMA1
59 111 P28066 PSMA5
54 106 O14818 PSMA7
56 114 Q8TAA3 PSMA8
61 113 P60900 PSMA6
57 109 P25787 PSMA2
56 109 P25789 PSMA4
59 111 P25788 PSMA3
57 107 P25786 PSMA1
112 170 P28066 PSMA5
107 161 O14818 PSMA7
115 169 Q8TAA3 PSMA8
114 168 P60900 PSMA6
110 163 P25787 PSMA2
110 164 P25789 PSMA4
112 166 P25788 PSMA3
108 161 P25786 PSMA1
171 225 P28066 PSMA5
162 216 O14818 PSMA7
170 224 Q8TAA3 PSMA8
169 225 P60900 PSMA6
164 217 P25787 PSMA2
165 222 P25789 PSMA4
167 222 P25788 PSMA3
162 220 P25786 PSMA1
226 241 P28066 PSMA5
217 248 O14818 PSMA7
225 256 Q8TAA3 PSMA8
226 246 P60900 PSMA6
218 234 P25787 P SMA2
223 261 P25789 PSMA4
223 255 P25788 PSMA3
221 263 P25786 PSMA1
Figure 4: Alignment of human PSMA subunits 1–8. Protein sequences of the eight proteasome PSMA subunits were aligned using Clustal
W. ⋆, identical residue in all seven subunits; :, conserved amino acids with strongly similar properties; ., conservation between residues of
weakly similar properties. Naturally occurring variants are highlighted with grey boxes. Alternatively spliced regions are underlined. Amino
acid residue numbers are shown on the left and right of each sequence and the UniProt accession number and gene name of each sequence
are shown to the right of each sequence. PSMA8 (PSMA7L) is found only in mammalian testis and is a spermatid/sperm-specific 𝛼 subunit
[33].
varies in different ethnic populations [60]. Subgroup analysis
of the −8C/G polymorphism data showed increased risks of
CAD in East Asians, with no significant associations among
other ethnic populations. Subgroup analysis also showed
increased risks of MI in all populations.
2.1.3. Type 2 Diabetes Mellitus. Interestingly, the same −8C >
G variant of PSMA6 gene that was associated with CAD
was found to be associated with T2DM and diabetes-related
metabolic traits in two Chinese populations [74]. 73 Cau-
casian patients with MI and 151 controls genotyped for
variants of the PSMA6 gene revealed no association between
PSMA6 −8C > G andMI [75]. However, 34 diabetic subjects
withMI showed a significant association with PSMA6 −8C >
G gene frequency compared to 85 controls [75]. Biopsy
specimens taken from the ischemic left ventricle of several
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1 33 Q99436 PSMB7
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1 12 P20618 PSMB1
1 29 P40306 PSMB10
1 45 P28074 PSMB5
1 43 P49720 PSMB3
1 36 P49721 PSMB2
8 55 P28065 PSMB9
17 69 P28072 PSMB6
34 78 Q99436 PSMB7
59 107 P28062 PSMB8
36 88 P28070 PSMB4
13 72 P20618 PSMB1
30 74 P40306 PSMB10
46 94 P28074 PSMB5
44 100 P49720 PSMB3
37 95 P49721 PSMB2
56 112 P28065 PSMB9
70 126 P28072 PSMB6
79 135 Q99436 PSMB7
108 165 P28062 PSMB8
89 148 P28070 PSMB4
73 129 P20618 PSMB1
75 131 P40306 PSMB10
95 152 P28074 PSMB5
101 158 P49720 PSMB3
96 151 P49721 PSMB2
113 166 P28065 PSMB9
127 181 P28072 PSMB6
136 189 Q99436 PSMB7
166 219 P28062 PSMB8
149 205 P28070 PSMB4
130 177 P20618 PSMB1
132 185 P40306 PSMB10
153 206 P28074 PSMB5
159 201 P49720 PSMB3
152 194 P49721 PSMB2
167 208 P28065 PSMB9
182 223 P28072 PSMB6
190 230 Q99436 PSMB7
220 262 P28062 PSMB8
206 248 P28070 PSMB4
178 237 P20618 PSMB1
186 226 P40306 PSMB10
207 249 P28074 PSMB5
202 205 P49720 PSMB3
195 201 P49721 PSMB2
209 219 P28065 PSMB9
224 239 P28072 PSMB6
231 277 Q99436 PSMB7
263 276 P28062 PSMB8
249 264 P28070 PSMB4
238 241 P20618 PSMB1
227 273 P40306 PSMB10
250 263 P28074 PSMB5
Figure 5: Alignment of human PSMB subunits 1–10. Protein sequences of the ten proteasome PSMA subunits were aligned using Clustal W.
⋆, identical residue in all ten subunits; :, conserved amino acids with strongly similar properties; ., conservation between residues of weakly
similar properties. Naturally occurring variants are highlighted with grey boxes. Alternatively spliced regions are underlined. Amino acid
residue numbers are shown on the left and right of each sequence and the UniProt accession number and gene name of each sequence are
shown to the right of each sequence.
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Figure 6: Phylogenetic tree of human 20S proteasome subunits.
Phylogenetic tree was generated using Clustal W2 phylogeny [88]
and image obtained using TreeView [89]. The UniProt accession
numbers used for the alignment of proteasome subunits are given
in Figures 4 and 5.
patients showed Ub levels and proteasome 20S activity
which significantly correlated with plasma glucose levels,
with T2DM patients having higher Ub levels and proteasome
20S activity than nondiabetics [75]. This experimental data
suggest that the PSMA6 −8C > Gpolymorphism contributes
toMI susceptibility in T2DM, possibly by upregulation of the
UPS.The PSMA6 −8C > G polymorphism was also reported
to be associatedwith lower survival rates inmultiplemyeloma
patients [93].
2.1.4. Graves’ Disease. Graves’ disease is an autoimmune
thyroid disease characterized by hyperthyroidism due to cir-
culating autoantibodies. It is one of themost common thyroid
problems and several immune and thyroid related genes
appear to influence susceptibility to Graves’ disease [94].
A 270 kb chromosome region (14q13.2-14q13) containing
PSMA6 was analyzed for polymorphisms and associations of
five microsatellite repeats in 50 Latvian patients with Graves’
disease and 116 controls with Graves’ disease [87]. Some
particular alleles of HSMS006 and HSMS801 (microsatellite
polymorphisms) were found more often while some alleles
of HSMS006 were found less frequently in Graves’ patients
when compared to healthy controls. The HSMS602 allele
was found in Graves’ patients but not in healthy controls
[87]. Further analysis is needed to confirm the importance
of PSMA6 in Graves’ disease.
2.1.5. Psoriasis. Several psoriasis susceptibility loci have now
been detected [95]. A meta-analysis of two GWA studies
involving 1,831 cases and 2,546 controls gave 102 potential
loci. A three-stage replication study using 4,064 cases and
4,685 controls from Michigan, Toronto, Newfoundland, and
Germany found three genomic regions, including one that
contains PSMA6 and NFKBIA (rs12586317) that showed
psoriasis susceptibility. The SNP rs12586317 was strongly
associated with the subphenotypes of psoriatic arthritis and
purely cutaneous psoriasis [95].
2.2. PSMA7. The proteasome gene PSMA7 codes for 𝛼4, a
248 residue protein that is similar to PSMA6 in structure.
It is also posttranslationally modified by phosphorylation,
glycosylation, and lysine acetylation [60, 84, 96]. Phospho-
rylation of 𝛼4 at Tyr 153 impaired G1/S transition and S/G2
progression in cells, suggesting that tyrosine phosphorylation
of the 𝛼4 proteasome subunit is important in intracellular
regulatory control [96].
2.2.1. Intellectual Disability. Sequencing the coding regions of
more than 21,000 genes from 100 patients with an IQ below 50
and their unaffected parents identified 79 de novo mutations
(affecting 77 genes) in 53 of 100 patients [45]. A de novo
heterozygous 335C-A transversion in PSMA7, resulting in an
A112D mutation, was identified in a male patient with severe
intellectual disability [45], suggesting that PSMA7 may be a
candidate intellectual-disability gene.
3. Immunoproteasome Mutations
and Polymorphisms
Specialized proteasomes called immunoproteasomes (Figure
3) are capable of cleaving substrates to generate short peptide
fragments that are recognized as antigens in lymphocytes [23,
29, 97]. These antigens are presented on the surface of these
cells (through the MHC complex) and play an important
role in the cell’s ability to mount a specific immune response
[97]. When an infection occurs, the hormone interferon
is excreted locally, resulting in gamma-interferon inducible
beta subunits which replace the constitutive beta subunits.
In many eukaryotic immunoproteasomes the 19S complex is
replaced by another complex, the PA28 (or 11S) complex.The
cytosolic PA28 complex is composed of a six-member ring
of PA28𝛼 and PA28𝛽 subunits which are products of PSME1
andPSME2 genes, respectively.Nuclear immunoproteasomes
contain a PA28𝛾 complex (PSME3 gene). The PA28 com-
plexes (caps) are significantly smaller than the 19S complexes
but are more efficient at generating antigen peptides. They
degrade proteins in an ATP-independent manner unlike the
26S proteasome [97, 98]. Two immunoproteasome genes,
PSMB8 and PSMB9, have been shown to be associated with
human diseases. Surprisingly, no polymorphisms in the genes
connected to the constitutive proteolytic activities of the
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Figure 7: Schematic diagram of PSMB8 showing the location of known polymorphisms. (a) Diagram of PSMB8 showing exon organization
(drawn to relative scale), location of alternative spliced region, propeptide region that is removed in themature form of the protein, location of
disease causing polymorphisms’, and location of other known polymorphisms. (b) Tertiary structure of 𝛽5i (PSMB8) showing polymorphisms
(shown in blue) associated with diseases. Structure created using PyMol (http://pymol.org/).
proteasome (PSMB5, PSMB6, and PSMB7) have been found
to be associated with disease. It is possible that polymor-
phisms in PSMB5, PSMB6, or PSMB7 that result in decreased
proteasome activity may be severe enough that they cause
embryonic lethality.
3.1. PSMB8. PSMB8 (proteasome subunit 𝛽 type 8) gene
expression is induced by interferon-𝛾 (IFN-𝛾), resulting in
the upregulation of the protein product of this gene, 𝛽5i,
which replaces the constitutive catalytic subunit 𝛽5 (PSMB5)
[99]. The human 𝛽5i is expressed as a 276 residue protein
which requires the proteolytic removal of 72 residues to
generate amature subunit [100]. Although the 𝛽5i propeptide
is not essential for incorporation into the 20S proteasome,
presence of this sequence increases the efficiency of 𝛽5i
incorporation and proteasome maturation [101]. Two alter-
native spliced forms of human 𝛽5i have been detected, but
both forms would result in the same mature protein, as
the alternative splicing occurs in the propeptide which is
missing in the mature form of 𝛽5i. The replacement of 𝛽5 by
𝛽5i increases the ability of the immunoproteasome to cleave
peptides after hydrophobic and basic residues. Mice lacking
the PSMB8 gene had reduced levels of MHC class I cell-
surface expression and inefficiently presented the endoge-
nous antigen HY [102]. A selective inhibitor of 𝛽5i, ONX-
0914 (previously referred to as PR-957), blocked presentation
of MHC class I-restricted antigens in vitro in splenocytes
and in vivo in mice [103]. In mouse models, inhibition
of 𝛽5i reversed signs of rheumatoid arthritis and reduced
cellular infiltration, cytokine production, and autoantibody
levels, suggesting that 𝛽5i has an important role in regulating
pathogenic immune responses [103]. PSMB8 has recently
been shown to have a role in cytokine production [103].ONX-
0914 blocked the production of IL-6, IL-23, and TNF-𝛼 by
∼50% or greater [103]. ONX-0914 also ameliorated disease in
two mouse models of arthritis [103].
Genetic variants of PSMB8 are associated with the
development of many diseases, including viral infection,
autoimmune disease, and malignant tumors. Figure 7 shows
a schematic diagram of the well-annotated polymorphisms
as well as the exon organization of PSMB8. The structure
of the protein product of PSMB8 showing the location of
the three residues associated with diseases is also shown
in Figure 7. The residues that are mutated by the disease-
associated polymorphisms in PSMB8 are highly conserved
from zebrafish to man (Figure 8).
3.1.1. JMP Syndrome. JMP syndrome (autosomal-recessive
autoinflammatory syndrome characterized by joint contrac-
tures, muscle atrophy, microcytic anemia, and panniculitis-
induced lipodystrophy) patients show hepatosplenomegaly
and hypergammaglobulinemia as well as lipodystrophy of the
arms, face, and thorax. Using genome-wide homozygosity
mapping, a homozygous missense mutation (c.224C > T,
Thr75Met) in the proteasome gene PSMB8 that encodes the
𝛽5i (LMP7) subunit was detected in two pedigrees from
Portugal and Mexico with JMP syndrome [54]. Segrega-
tion of this mutation in other members of the pedigrees
occurred in an autosomal-recessive fashion. Measurement of
proteasome activity in the cell lysates of Epstein-Barr virus-
transformed lymphoblasts from a control subject and an
affected (T75M) patient showed reduced chymotrypsin-like
activity, but similar trypsin-like and caspase-like activity in
the affected patient relative to the control subject. Serum
from two affected patients showed 2.8- to 3.5-fold, 1.6- to
>9-fold, and 7- to 19-fold increased levels of interferon 𝛾,
IL-8, and IL-6 respectively. These results and other results
from these patients, such as increased serum 𝛾 globulins and
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Figure 8: Sequence alignment of human PSMB8 from different animals. Protein sequences of Rattus norvegicus (rat), Bos taurus (bovine),
Canis familiaris (dog),Mus musculus (mouse),Homo sapiens (human), Danio rerio (Zebrafish), Felis catus (Cat), Xenopus tropicalis (western
clawed frog), Ornithorhynchus anatinus (Duckbill platypus), Xenopus laevis (African clawed frog), and Equus caballus (Horse) PSMB8 were
aligned using Clustal W. ⋆, identical residue in all six subunits; :, conserved amino acids with strongly similar properties; ., conservation
between residues of weakly similar properties. Naturally occurring variants are highlighted with grey boxes. Alternatively spliced regions are
underlined. Amino acid residue numbers are shown on the left and right of each sequence and the UniProt accession number is also shown.
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erythrocyte sedimentation rate without elevation in other
cytokines such as IL-1 andTNF-𝛼, suggest significant ongoing
inflammation and a potentially unique biomarker signature
in JMP syndrome patients.
3.1.2. Nakajo-Nishimura Syndrome. Nakajo-Nishimura syn-
drome (NNS) was first reported by Nakajo in 1939 [104].
NNS is a rare, distinct inflammatory, and wasting disease
which usually begins in early infancy and has only been
reported in Japanese patients [105]. Clinical features of this
disease include elongated and thickened fingers, hereditary
lipomuscular atrophy with joint contractures, periodic high
fever, hyper-𝛾-globulinemia nodular erythema, and myositis
[106, 107]. Extracts separated by glycerol gradient centrifu-
gation from immortalized lymphoblastoid cell lines obtained
from an NNS patient, his heterozygous parent, and a healthy
control showed that all three proteolytic activities of the
proteasome were decreased in the NNS patient relative to
the healthy control. Due to the low number of samples
investigated, the results should be viewed with caution but do
suggest that the G210Vmutation is associated with decreased
immunoproteasome activity. NNS cells also show an accu-
mulation of immature 20S proteasome precursors before
incorporation of 𝛽5i into the complex. In silico modeling
of the G210V suggests that this assembly defect could be
due to the proximity of 𝛽5i, 𝛽4, and 𝛽6 next to each other
resulting in conformation changes in both Thr73 and Lys105
which are part of the catalytic center of PSMB8. Interestingly,
some of the G210V mutant 𝛽5i subunits incorporated into
the mature proteasome appeared to be insufficiently cleaved.
These results suggest that the G210V mutation affects both
𝛽5i catalytic activity and assembly of the 20S proteasome.
A polymorphism in PSMB8 resulting in a Q49K amino
acid change in 𝛽5i was found to be associated with juvenile
rheumatoid arthritis [108]. Some of the features of juvenile
rheumatoid arthritis are similar to NNS.
3.1.3. Candle Syndrome. Chronic atypical neutrophilic der-
matosis with lipodystrophy and elevated temperature (CAN-
DLE syndrome) is a recently described autoinflamma-
tory syndrome [77]. Autoinflammatory diseases differ from
autoimmune diseases in that they are primarily a result of
alterations in the innate immune system instead of pertur-
bations in adaptive immunity [109]. Patients with CANDLE
syndrome typically show recurrent fevers, hypochromic or
normocytic anemia, delayed physical development, and vari-
able clinical features including acanthosis nigricans (skin
hyperpigmentation), alopecia areata (spot baldness), and
hypertrichosis (werewolf syndrome) [109, 110]. A recent
genome-wide analysis of nine affected patients in eight
families suggests that mutations in PSMB8 may be the
molecular basis of CANDLE syndrome [55]. Four patients
were homozygous and two were heterozygous for a missense
mutation (c.224C > T), two patients were homozygous for a
nonsense mutation in PSMB8 (c.405C > A), and one patient
showed no mutation. None of these sequence changes were
observed in chromosomes from 750 healthy controls. Only
two of the four patients with the same mutation shared the
same haplotype, indicating a mutational hot spot.
3.1.4. Bacterial Infection. Mycobacterium tuberculosis (M.
tuberculosis) infection is a common bacterial infection that
is the leading cause of morbidity and mortality compared to
all other infectious agents [111]. Extrapulmonary tuberculosis,
which is common in the intestinal tract, bones, kidney, lymph
gland, skin, and other organs, occurs in 5–20% of all tubercu-
losis cases and is increasing in both developed and developing
countries [112]. Using PCR-based restriction digest, sequenc-
ing of digests, and logistic regression analysis, a study involv-
ing 168 Chinese patients with intestinal tuberculosis and
235 normal controls identified a polymorphism in PSMB8
(Q145K)whichwere found to be associatedwith intestinalM.
tuberculosis infection [78].M. tuberculosis antigenic peptides
are produced by the immunoproteasome and subsequently
presented on the cell surface by the MHC-I molecule result-
ing in CD8+ cytotoxic T lymphocytes eliminating M. tuber-
culosis infected cells. Mice lacking the three immunoprotea-
some catalytic subunits showed defects in presenting several
major histocompatibility complex (MHC) class I epitopes in
dendritic cells [113]. During viral infection in vivo, the MHC
class I-presented peptides in immunoproteasome-deficient
animals were significantly reduced compared with wild-
type mice, whereas presentation of MHC class II peptides
was unaffected. These reductions in MHC class I-presented
peptides and changes in the type of class I-presented peptides
caused transplant rejection of wild-type cells in mutant mice
[113].
3.1.5. Cancer. A high risk of colon cancer was associated
with a LMP7-K/Q genotype (PSMB8) while a low risk was
associated with the LMP7-Q/Q genotype in an investigation
of 112 colorectal carcinoma patients and 62 control patients
[79]. Stimulation of colon carcinoma cell lines with interferon
(IFN)-𝛾 exhibited a 10-fold increase in LMP7-Q transcript
amounts, but only 3.8-fold increase in LMP7-K [79]. The
LMP7-K allele showed reduced transcript stability compared
with LMP7-Q. Overall, the LMP7-K allele seems to reduce
the immunoproteasome formation which results in reduced
peptide processing and reduced peptide-HLA presentation
[79]. Peptide-HLA presentation is a crucial factor in the
immune response against cancer. Immunoproteasomes gen-
erate immunogenic tumor peptides which are important
for the destruction of cancer cells by cytotoxic T lympho-
cytes.
3.1.6. Ankylosing Spondylitis. Ankylosing spondylitis (AS) is
an inflammatory rheumatic disease which affects men more
often than women and is strongly associated with human
leucocyte antigen (HLA)-B27 andwith the fusion of the spine
vertebrae [114]. Inflammation of the joints is common in AS
but other parts of the body, such as eyes and bowels, can also
show inflammation.The first study to suggest that the PSMB8
gene was associated with AS involved 57 AS patients and
102 matched random controls [80]. This investigation found
that the HLA-B27 polymorphism in PSMB9 and LMP7-Q/Q
(PSMB8) confers a higher relative risk than with HLA-B27
alone. A significant association was observed between the
LMP7-Q/Q genotype and AS.
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3.1.7. Type 1 Diabetes Mellitus. A genomic polymorphism
(G/T-37360) in PSMB8 was strongly associated with type 1
diabetes mellitus (T1DM) in an investigation of 198 unre-
lated T1DM Caucasian patients and 192 normal Caucasian
controls from the southeastern United States [81]. The R/H-
60 polymorphism in PSMB8 was found to be associated
with T1DM only in subjects containing an HLA DR4-
DQB1∗0302 haplotype.However, results from this same study
suggest that PSMB8 genes have independent effects on T1DM
susceptibility [81].
Some of the clinical features of PSMB8mutations may be
due to the role of PSMB8 in autophagy as PSMB8 seems to
play a key role in apoptosis. IFN-𝛾 causes increased sensitivity
to apoptosis in atherosclerotic lesions. IFN-𝛾 sensitized cells
from the fibrous cap of human atherosclerotic lesions showed
reduced Mcl-1, phospho-Bcl-2 (S70), and phospho-Bcl-X(L)
(S62) protein levels. Knockdown of PSMB8 with siRNA
protected the antiapoptotic protein Mcl-1 from degradation
[115]. These results suggest that the immunoproteasome may
be a key link between inflammatory factors and the control
of vascular cell apoptosis [115].
3.2. PSMB9. Like PSMB8 expression, PSMB9 gene expres-
sion is induced by IFN-𝛾, resulting in the upregulation of
the protein product of this gene 𝛽1i, which replaces the
constitutive catalytic subunit 𝛽1 (PSMB6) [99]. The human
𝛽1i is expressed as a 219 residue protein which requires
the proteolytic removal of 20 residues to generate a mature
subunit. Although two alternative transcripts which encode
different isoforms have been reported (Figure 5), the alterna-
tive splicing occurs in the region of 𝛽1i (propeptide) that is
removed in the mature form, resulting in the same mature
protein. Upregulation of MHC-linked 𝛽1i and 𝛽5i subunits
amplifies specific endopeptidase activities of the proteasome
resulting in the increased production of peptides which ter-
minate almost exclusivelywith hydrophobic or basic residues,
such as those found on MHC class I molecules [99, 116].
𝛽1i-deficient mice, generated by replacing a 800 bp
region of the PSMB9 gene with a neomycin resistance gene
in embryonic stem cells, were viable, and healthy with no
gross anatomical abnormalities [117]. Purified proteasomes
from the spleen and liver of 𝛽1i-deficient mice showed lower
peptidase activity against hydrophobic and basic substrates
(but not acidic substrates) when compared to purified protea-
somes from wild-type tissues. Antigen-presenting cells from
𝛽1i-deficient mice displayed reduced ability to stimulate a T-
cell hybridoma specific for a nucleoprotein envelope antigen
of an influenza A virus [117]. 𝛽1i-deficient mice also showed
only 60%–70% of wild-type levels of CD8-positive T lympho-
cytes and generated fewer influenza nucleoprotein-specific
cytotoxic T lymphocyte precursors. Hence 𝛽1i is important
in antigen processing of MHC class I-restricted anti-
gens.
3.2.1. Graves’ Disease. Several investigations demonstrated
potential associations between codon 60 R/H polymorphism
in PSMB9 (p.60R > H; c.179G > A; rs17587) and increased
susceptibility to various diseases. This PSMB9 genetic R/H
polymorphism at codon 60 had H allele frequencies of 1.1%
to 34%, depending on ethnic group [118, 119]. DNA from 306
Caucasian patients with Graves’ disease and 364 Caucasian
control subjects were investigated for the distribution of
an R/H polymorphism in the PSMB9 gene and a G/T
polymorphism in the PSMB8 gene [82]. The R allele and the
RH genotype were increased in subjects with Graves’ disease
when compared with control subjects. Independently, DNA
from 129 families, including parents, an affected sibling with
Graves’ disease, and an unaffected sibling, were investigated.
No preferential allelic transmission occurred from heterozy-
gote parents to offspring at either locus, suggesting that the
association of the R/H polymorphism at codon 60 of PSMB9
with Graves’ disease is due to linkage disequilibrium with the
associated HLA haplotype [82].
Mishto et al., 2006, [120] found that the codon 60
R/H polymorphism results in a decreased chymotrypsin-
like proteasome activity in the aged brain, while recombi-
nant peptides mimicking endogenous substrates showed no
differences in the substrate hydrolysis profiles between the
codon 60 genotypes [121]. Using fluorogenic substrates that
are hydrolyzed selectively by𝛽1i, measurement of𝛽1i catalytic
activity showed that the codon 60 R/H polymorphism did
not alter the activity of 𝛽1i among the cancer cell lines tested
[122]. Western blotting showed that the levels of 𝛽1i were
highly elevated in clinical colon cancer tissues compared to
the paired nonmalignant colonic tissues. These effects all
suggest inconsistent results regarding the influence of this
polymorphism on proteasome activity.
3.2.2. Colorectal Cancer. Genotyping of 1467 SNPs (in 871
candidate cancer genes) in 2575 Caucasian colorectal cancer
patients and 2707 controls indicated an association with 44
SNPs and colorectal cancer [123]. One of these SNPs, rs241419
(V32I) in PSMB9, showed a significant association with an
increased risk of colorectal cancer. However, validation of
rs241419 association with colorectal cancer was not carried
out using kin-cohort analysis of first-degree relatives as was
carried out for some other SNPs validated [123].
3.2.3. Ankylosing Spondylitis. 193 unrelated Caucasians and
49 Chinese B27 individuals with AS were investigated to
determine PSMB9 gene influence on disease susceptibility in
HLA-B27 individuals with AS [83]. HLA-B27 typing showed
the involvement of the PSMB9 gene in the expression of AS in
B27 individuals. The LMP2BB genotype (PSMB9) was inves-
tigated in 546 AS patients (41 Caucasians and 17 Mexican)
and 4352 controls. The LMP2BB genotype was significantly
decreased in Caucasian and Mexican AS patients compared
to random Mexican and Caucasian controls, respectively
[124].
3.2.4. 19S Proteasome Mutations and Polymorphisms. Align-
ment of human PSMC (Figure 9) and human PSMD
(Figure 10) shows the relatedness of the 19S proteasome sub-
units. PSMF1 shares some homology with PSMD12 (approx-
imately 40%) while PSMD8 shares homology with PSME4
(approximately 40%) (Figure 11). Limited data suggests that
four 19S genes, PSMD3, PSMD7, PSMD13, and PSMD14, may
be associated with human diseases.
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400 409 Q75L23 PSMC2
435 439 P17980 PSMC3
398 406 P62195 PSMC5
383 389 P62333 PSMC6
414 418 P43686 PSMC4
Figure 9: Alignment of human PSMC subunits 1–6. Protein sequences of the six proteasome PSMC subunits were aligned using Clustal W.
⋆, identical residue in all six subunits; :, conserved amino acids with strongly similar properties; ., conservation between residues of weakly
similar properties. Naturally occurring variants are highlighted with grey boxes. Alternatively spliced regions are underlined. Amino acid
residue numbers are shown on the left and right of each sequence and the UniProt accession number and gene name of each sequence are
shown to the right of each sequence.
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1 30 O00231 PSMD11
1 0 O00233 PSMD9
1 0 Q99460 PSMD1
1 0 075832 PSMD10
1 0 Q9UNM6 PSMD13
1 3 000232 PSMD12
1 43 O43242 PSMD3
1 53 P48556 PSMD8
1 2 Q16401 PSMD5
1 0 P51665 PSMD7
1 31 Q13200 PSMD2
1 0 P55036 PSMD4
1 0 O00487 PSMD14
1 30 Q15008 PSMD6
31 57 PSMD11
1 0 PSMD9
1 14 PSMD1
1 0 PSMD10
1 17 PSMD13
4 28 PSMD12
44 88 PSMD3
54 104 PSMD8
3 16 PSMD5
1 0 PSMD7
32 65 PSMD2
1 0 PSMD4
1 0 PSMD14
31 90 PSMD6
58 86 PSMD11
1 10 PSMD9
15 61 PSMD1
1 0 PSMD10
18 39 PSMD13
29 57 PSMD12
89 110 PSMD31
05 138 PSMD8
17 42 PSMD5
1 0 PSMD7
66 123 PSMD2
1 0 PSMD4
1 0 PSMD14
91 130 PSMD6
87 111 PSMD11
11 10 PSMD9
62 103 PSMD1
1 0 PSMD10
40 87 PSMD13
58 75 PSMD12
111 138 PSMD3
139 147 PSMD8
43 50 PSMD5
1 0 PSMD7
124 165 PSMD2
1 0 PSMD4
1 0 PSMD14
131 168 PSMD6
112 126 PSMD11
11 10 PSMD9
104 156 PSMD1
1 0 PSMD10
88 124 PSMD13
76 90 PSMD12
139 177 PSMD3
148 166 PSMD8
51 50 PSMD5
1 0 PSMD7
166 210 PSMD2
Figure 10: Continued.
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1 0 PSMD4
1 0 PSMD14
169 203 PSMD6
127 152 PSMD11
11 10 PSMD9
157 203 PSMD1
1 0 PSMD10
125 167 PSMD13
91 123 PSMD12
178 225 PSMD3
167 193 PSMD8
51 50 PSMD5
1 0 PSMD7
211 254 PSMD2
1 0 PSMD4
1 0 PSMD14
204 231 PSMD6
153 170 PSMD11
11 10 PSMD9
204 233 PSMD1
1 5 PSMD10
168 204 PSMD13
124 167 PSMD12
226 257 PSMD3
194 234 PSMD8
51 51 PSMD5
1 0 PSMD7
255 308 PSMD2
1 0 PSMD4
1 0 PSMD14
232 232 PSMD6
171 180 PSMD11
11 10 PSMD9
234 279 PSMD1
6 22 PSMD10
205 234 PSMD13
168 214 PSMD12
258 287 PSMD3
235 255 PSMD8
52 79 PSMD5
1 0 PSMD7
309 349 PSMD2
1 43 PSMD4
1 0 PSMD14
233 232 PSMD6
181 180 PSMD11
11 10 PSMD9
280 334 PSMD1
23 22 PSMD10
235 237 PSMD13
215 229 PSMD12
288 343 PSMD3
256 288 PSMD8
80 79 PSMD5
1 0 PSMD7
350 361 PSMD2
44 72 PSMD4
1 0 PSMD14
233 232 PSMD6
181 210 PSMD11
11 11 PSMD9
335 385 PSMD1
23 39 PSMD10
238 237 PSMD13
Figure 10: Continued.
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230 257 PSMD12
344 357 PSMD3
289 300 PSMD8
80 86 PSMD5
1 0 PSMD7
362 389 PSMD2
73 93 PSMD4
1 0 PSMD14
233 232 PSMD6
211 250 PSMD11
12 31 PSMD9
386 433 PSMD1
40 71 PSMD10
238 250 PSMD13
258 270 PSMD12
358 377 PSMD3
301 307 PSMD8
87 115 PSMD5
1 0 PSMD7
390 441 PSMD2
94 142 PSMD4
1 0 PSMD14
233 232 PSMD6
251 273 PSMD11
32 33 PSMD9
434 477 PSMD1
72 106 PSMD10
251 276 PSMD13
271 292 PSMD12
378 408 PSMD3
308 320 PSMD8
116 137 PSMD5
1 0 PSMD7
442 481 PSMD2
143 195 PSMD4
1 10 PSMD14
233 232 PSMD6
274 294 PSMD11
34 46 PSMD9
478 505 PSMD1
107 124 PSMD10
277 304 PSMD13
293 309 PSMD12
409 431 PSMD3
321 325 PSMD8
138 197 PSMD5
1 11 PSMD7
482 509 PSMD2
196 233 PSMD4
11 34 PSMD14
233 232 PSMD6
295 322 PSMD11
47 46 PSMD9
506 541 PSMD1
125 144 PSMD10
305 336 PSMD13
310 347 PSMD12
432 460 PSMD3
326 345 PSMD8
198 245 PSMD5
12 25 PSMD7
510 546 PSMD2
234 284 PSMD4
35 42 PSMD14
233 232 PSMD6
Figure 10: Continued.
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323 343 PSMD11
47 64 PSMD9
542 577 PSMD1
145 190 PSMD10
337 347 PSMD13
348 371 PSMD12
461 474 PSMD3
346 350 PSMD8
246 295 PSMD5
26 68 PSMD7
547 588 PSMD2
285 328 PSMD4
43 85 PSMD14
233 232 PSMD6
344 367 PSMD11
65 108 PSMD9
578 616 PSMD1
191 210 PSMD10
348 360 PSMD13
372 395 PSMD12
475 486 PSMD3
351 350 PSMD8
296 330 PSMD5
69 105 PSMD7
589 640 PSMD2
329 340 PSMD4
86 122 PSMD14
233 232 PSMD6
368 404 PSMD11
109 145 PSMD9
617 639 PSMD1
211 226 PSMD10
361 360 PSMD13
396 425 PSMD12
487 486 PSMD3
351 350 PSMD8
331 371 PSMD5
106 122 PSMD7
641 700 PSMD2
341 340 PSMD4
123 122 PSMD14
233 246 PSMD6
405 421 PSMD11
146 149 PSMD9
640 669 PSMD1
227 226 PSMD10
361 360 PSMD13
426 445 PSMD12
487 486 PSMD3
351 350 PSMD8
372 379 PSMD5
123 170 PSMD7
701 738 PSMD2
341 340 PSMD4
123 139 PSMD14
247 246 PSMD6
422 422 PSMD11
150 160 PSMD9
670 726 PSMD1
227 226 PSMD10
361 360 PSMD13
446 456 PSMD12
487 486 PSMD3
351 350 PSMD8
380 397 PSMD5
Figure 10: Continued.
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171 209 PSMD7
739 758 PSMD2
341 340 PSMD4
140 171 PSMD14
247 256 PSMD6
423 422 PSMD11
16 211 PSMD9
727 771 PSMD1
227 226 PSMD10
361 360 PSMD13
457 456 PSMD12
487 486 PSMD3
351 350 PSMD8
398 429 PSMD5
210 249 PSMD7
759 808 PSMD2
341 340 PSMD4
172 200 PSMD14
257 284 PSMD6
423 422 PSMD11
212 223 PSMD9
772 812 PSMD1
227 226 PSMD10
361 375 PSMD13
457 456 PSMD12
487 506 PSMD3
351 350 PSMD8
430 474 PSMD5
250 271 PSMD7
809 840 PSMD2
341 344 PSMD4
201 244 PSMD14
285 326 PSMD6
423 422 PSMD11
224 223 PSMD9
813 868 PSMD1
227 226 PSMD10
376 376 PSMD13
457 456 PSMD12
507 529 PSMD3
351 350 PSMD8
475 477 PSMD5
272 324 PSMD7
841 860 PSMD2
345 377 PSMD4
245 283 PSMD14
327 368 PSMD6
423 422 PSMD11
224 223 PSMD9
869 928 PSMD1
227 226 PSMD10
377 376 PSMD13
457 456 PSMD12
530 534 PSMD3
351 350 PSMD8
478 498 PSMD5
325 324 PSMD7
861 908 PSMD2
378 377 PSMD4
284 310 PSMD14
369 389 PSMD6
423 422 PSMD11
224 223 PSMD9
929 953 PSMD1
227 226 PSMD10
377 376 PSMD13
457 456 PSMD12
535 534 PSMD3
351 350 PSMD8
499 504 PSMD5
325 324 PSMD7
909 908 PSMD2
378 377 PSMD4
311 310 PSMD14
390 389 PSMD6
Figure 10: Alignment of humanPSMDsubunits 1–14. Protein sequences of the thirteen proteasomePSMDsubunits were aligned usingClustal
W.No residues are conserved in all PSMD subunits. Naturally occurring variants are highlightedwith grey boxes. Alternatively spliced regions
are underlined. Amino acid residue numbers are shown on the left and right of each sequence and the UniProt accession number and gene
name of each sequence are shown to the right of each sequence.
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0.1
PSMF1
PSMD12
PSMD9
PSMD5
PSMD14
PSMD7
PSMC3
PSMC1
PSMC4
PSMC6
PSMC2
PSMC5
PSMD11
PSMD6
PSMD2
PSMD1
PSMD10
PSMD3
PSMD4
PSMD8
PSME4
PSMD13
PSME3
PSME2
PSME1
Figure 11: Phylogenetic tree of human PSMC, PSMD, PSME, and
PSMF proteasome subunits. Phylogenetic tree was generated using
Clustal W2 phylogeny [88] and image obtained using TreeView
[89]. The UniProt accession numbers used for the alignment of
proteasome subunits are given in Figures 9, 10, 12, and 13.
3.3. PSMD3. The PSMD3 gene encodes a member of the pro-
teasome 19S regulatory cap, Rpn3. Rpn3 is one of the non-
ATPase subunits and is composed of 534 amino acids.PSMD3
variants are associated with insulin resistance in different
populations and these relationships are likely to be modified
by dietary factors [76]. Insulin resistance is critical in the
pathogenesis of chronic diseases such as CAD, hypertension,
inflammation, and T2DM [125, 126].
3.3.1. Diabetes as Related to Insulin and Dietary Intake. The
UPS has been shown to regulate insulin signal transduction
via several mechanisms, including regulation of glucose
transporters, ubiquitination of the insulin receptor, and
degradation of insulin receptor substrate [127]. Ten SNPs
covering 90% the genetic variations in or near PSMD3 were
investigated. Using two independent groups: the GOLDN
(Genetics of Lipid Lowering Drugs and Diet Network)
study which included 820 participants of Northern European
origin, and the BPRHS (Boston Puerto Rican Health Study)
study, which included 844 participants recruited by the
Boston Puerto Rican Center for Population Health and
Health Disparities, the minor C allele carriers of the SNP
rs4065321 had a higher homeostasis model assessment of
insulin resistance than noncarriers in males of both studies.
An interaction between SNP rs709592 and dietary carbohy-
drate on a higher homeostasis model assessment of insulin
resistance subjects with the T allele was detected in the
GOLDN group. SNPs rs4065321 and rs709592 both signifi-
cantly interacted with dietary factors in the GOLDN study.
3.3.2. White Blood Cell Count. Total white blood cell (WBC)
and neutrophil counts vary among different ancestry groups
and are lower among individuals of African descent [128].
Measuring WBCs in humans is universally used in diseased
and asymptomatic patients to identify or predict chronic
disease. WBCs are made up mostly of neutrophils, which
are a key component of the innate immune system as an
early line of defense against invading microorganisms. Very
low numbers of neutrophils have been shown to make
patients susceptible to bacterial infections and can lead to
lethal conditions [129]. PSMD3 has also been reported to
be associated with white blood cell counts [130–132]. The
rs4065321 of PSMD3-CSF3 region was associated with WBC
count in African American and other populations. GWA
analysis of 13,923 subjects in the electronic Medical Records
and Genomics (eMERGE) Network identified two regions
each unique to subjects of genetically determined ancestry
to the African continent or to the European continent [131].
One of these regions contained the PSMD3 intronic SNP
rs4065321 (in persons of European ancestry) that was found
to be significantly associated with WBC count [131]. A
GWA study in 5771 Japanese and a replication study using
independent 1894 Japanese identified rs4794822 in PSMD3-
CSF3 as being significantly associated with neutrophil count
[132].The SNP rs4794822 in PSMD3-CSF3was not associated
with lymphocyte, monocyte, eosinophil, or basophil counts,
suggesting a specific association with neutrophils [132].
3.4. PSMD7. PSMD7, the 19S proteasome non-ATPase regu-
latory subunit 7, encodes the protein Rpn8, which is involved
in the ATP-dependent degradation of ubiquitinated proteins
[133]. Rpn8 is a 324 residue protein which is modified by
acetylation of K204 and K214 and may be involved in viral
replication [84, 134]. The HIV-1 accessory gene product Vpr
interacts with MOV34 (homologous to PSMD7) [134]. The
induction of cell cycle arrest at the G2/M phase border by
Vpr correlated with a change in the subcellular localization of
MOV34 from a nuclear to a perinuclear localization as well as
the inhibition of the maturation promoting factor-associated
histone H1 kinase activity. These results suggest that PSMD7
may be involved in the regulation of the cell cycle and is a
likely cofactor for HIV-1 Vpr [134].
3.4.1. Ankylosing Spondylitis. Blood samples from 185 Chi-
nese patients with AS (149 male) and 516 healthy controls
(412 male) showed that SNP rs17336700 of PSMD7 is signif-
icantly associated with AS in a Chinese population [18]. Two
mutations, 392-187C → T and 392-192delTC, were detected
once in the AS patients. The SNP rs17336700 had a minor
allele frequency of 13.0% and was significantly increased
in AS patients relative to controls. Allele-wise analysis also
indicated a higher frequency of the rs17336700 C allele in
22 Scientifica
patients when compared to controls [18]. Human liver biopsy
samples from 73 patients (containing eight rs17336700 TC
heterozygotes) showed that PSMD7 gene expression in the
TC group was 1.88-fold higher than that of the TT group.
3.5. PSMD13. PSMD13 is one of the least understood pro-
teasome genes. It codes for a 376 amino acid protein called
Rpn9 which is part of the 19S regulatory cap that is involved
in the ATP-dependent degradation of ubiquitinated proteins
[135]. Two isoforms of PSMD13 are produced in humans
by alternative splicing and its translated product Rpn11 is
acetylated at K298 [84].
3.5.1. Platelet Traits. Platelet traits have been shown to be
highly heritable and well established as being important for
the pathogenesis of atherothrombosis and cancer. Investi-
gation of genetic variants associated with platelet traits iden-
tified five chromosomal regions associated with variation in
the number of circulating platelets (PLT) and eight associated
with mean platelet volume (MPV) variation with genome-
wide significance [136]. Several SNPs near the telomere
region of chromosome 11p were associated with PLT. This
region contains six genes, including PSMD13. Likemost com-
plex diseases multiple genetic loci influence interindividual
variation in platelet traits.
3.6. PSMD14. PSMD14 codes for Rpn11 which is a metallo-
protease (binds zinc) that specifically cleaves K63-linked but
not K48-linked polyubiquitin chains [137]. As part of the
19S, Rpn11 is involved in the ATP-dependent degradation of
ubiquitinated proteins. Rpn11 is a 310 residue protein which
is important for recycling Ub from proteasome substrates
and is also a key deubiquitinating enzyme for regulating
Ub conjugates generated in response to DNA damage as
well as several aspects of the mammalian DNA double-
strand break response [138]. In Schizosaccharomyces pombe,
the yeast equivalent of PSMD14 (POH1), has been shown to
confer pleiotropic drug resistance to taxol, doxorubicin, 7-
hydroxystaurosporine, and ultraviolet light when transiently
overexpressed in mammalian cells [139]. These experimental
data all suggest that Rpn11 is important in cellular susceptibil-
ity to cytotoxic agents. Rpn11 is known to be phosphorylated
on S150 and S224 [140].
3.6.1. Intellectual Disability. PSMD14 is part of a 0.4Mb
region of 2q24.2 that is associated with intellectual disability
and short stature [141]. An 18-year-old male with mild intel-
lectual disability and short stature had a 0.422Mb deletion
on 2q24.2 which was detected by comparative genomic
hybridization. This deleted region included three genes:
TBR1, TANK, and PSMD14 [141]. While it is not known if all
three genes are important for the phenotype, the association
of other proteasome genes with intellectual disability suggests
that PSMD14 is a possible candidate gene that may be
associatedwith intellectual disability.Theproteasome is likely
involved in intellectual disabilities indirectly by altering the
degradation of key signaling proteins important for intel-
lect.
4. Polymorphism Associated with
Reduced Risk of Disease
4.1. Multiple Sclerosis. Multiple sclerosis (MS) is a common
but complex autoimmune disease which displays accumu-
lated immunoproteasomes in plaques of affected brain areas.
The immunoproteasome PSMB9 codon 60HH variant was
observed to have a reduced risk of developing MS in HLA-
A∗02+ Italian females [142]. Although the role of the pro-
teasome in autoimmune diseases is only partly understood,
the treatment of autoimmune diseases with proteasome
inhibitors has been successful in animal models [143, 144].
Production of MHC class I-restricted epitopes by the protea-
some is a key step in the activation and regulation of autoreac-
tive CD8+ T cells. Immunoproteasomes carrying the PSMB9
60Hallele show a lower amount of theHLA-A∗0201 restricted
epitope myelin basic protein residues 111–119 (MBP
111–119)
in vitro [142]. It is possible that the altered proteasome-
dependent production of a specificMBP epitope presented on
the MHC class I may be important in MS pathogenesis [142].
4.2. Effect of Reduced Copy Number of a Proteasome Gene on
Disease Susceptibility. Another way by which the proteasome
may contribute to disease is by increasing disease related
liability in cells, thereby resulting in reduced numbers of dis-
eased cells. A distinct class of cancer-specific liabilities result-
ing from genome instability was recently reported [145].
Utilization of both genome wide copy number and loss of
function data (RNAi profiles) from 86 cancer cell lines iden-
tified predominantly proteasome, spliceosome, and ribosome
components that were associated with associated with copy-
number loss [145]. Cells containing partial PSMC2 copy-
number loss lack a proteasome complex composed of the
protein product of PSMC2, Rpt1, and three other 19S subunits
and eventually die after PSMC2 suppression [145].
5. Polymorphisms in Genes That Code for
Proteins Which Directly Interact and Affect
Proteasome Function
Besides directly having polymorphisms on proteasome sub-
units which affect proteasome function, proteasome inter-
acting proteins are also likely to have mutations that affect
proteasome function. An E201 deletion in the proteasome
26S ATPase subunit 3-interacting protein (PSMC31P), which
is highly expressed in testis and colon, has been associated
with XX ovarian dysgenesis [146]. XX ovarian dysgenesis
is characterized by primary amenorrhea, lack of sponta-
neous pubertal development, hypergonadotropic hypogo-
nadism, and uterine hypoplasia as a result of streak gonads
[146]. PSMC3IP enhances the meiotic recombination protein
DMC1-mediated strand exchange needed for pairing homol-
ogous chromosomes during meiosis and has been shown
to modulate the activity of proteasomes through association
with PSMC3 [146–148]. However, the effect of the E201 dele-
tion on proteasome function has not been determined.
Polymorphisms in other proteins such as the proteasome
maturation protein (POMP) are also known to be associated
with rare diseases. A one base pair deletion (−95C) in POMP
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1 57 Q06323 PSME1
1 60 Q9UL46 PSME2
1 58 P61289 PSME3
58 113 Q06323 PSME1
61 103 Q9UL46 PSME2
59 118 P61289 PSME3
114 173 Q06323 PSME1
104 163 Q9UL46 PSME2
119 178 P61289 PSME3
174 233 Q06323 PSME1
164 223 Q9UL46 PSME2
179 238 P61289 PSME3
234 249 Q06323 PSME1
224 239 Q9UL46 PSME2
239 254 P61289 PSME3
Figure 12: Alignment of human PSME subunits 1–3. Protein sequences of the three proteasome PSME subunits were aligned using ClustalW.
⋆, identical residue in all six subunits; :, conserved amino acids with strongly similar properties; ., conservation between residues of weakly
similar properties. Naturally occurring variants are highlighted with grey boxes. Alternatively spliced regions are underlined. Amino acid
residue numbers are shown on the left and right of each sequence and the UniProt accession number and gene name of each sequence are
shown to the right of each sequence.
is associated with keratosis linearis, ichthyosis congenital,
and sclerosing keratoderma (KLICK syndrome) in several
European families [149]. POMP associates with 𝛼 and 𝛽
proteasome intermediates and facilitates the assembly of 𝛽
subunits onto the 𝛼 subunit rings [101, 150]. Investigation
of skin biopsies from KLICK syndrome patients showed
altered epidermal distribution of POMP, 𝛼4 (PSMA7), and
𝛽5 (PSMB5), when compared to controls [149]. KLICK
syndrome is therefore most likely associated with impaired
proteasome assembly which would result in altered pro-
teasome activity and function. Measurement of proteasome
activity in diseased skin samples is needed to determine if
proteasome activity is decreased.
6. Problems Associated with
Proteasome Activity Measurements and
Need for Measurement of All Proteasome
Proteolytic Activities
Both where (from what tissue) and how the proteasome
activity is measured are important. Proteasome activity mea-
surements in different human tissues require a basic under-
standing of the numerous nonproteasomal proteases in tis-
sues (some of which can also cleave proteasomal substrates)
and the proper use of proteasome-specific inhibitors. While
the most commonly used proteasome inhibitor, MG132, is
cheap andworkswell as a proteasome inhibitor formeasuring
chymotrypsin-like activity of the proteasome, it is not a
good inhibitor for measuring the caspase-like or trypsin-like
activity of the proteasome. MG132 is known to inhibit other
proteases besides the proteasome including calpains [151] and
cathepsins A, B, and K [152–154].
The source of the sample is also important, since pro-
teasomes show tissue-dependent differences in composition,
interacting partners, and posttranslational modifications,
possibly due to differences in protein expression in tissues
[155]. All proteasome measurements related to diseased tis-
sues containing proteasome polymorphisms reported so far
measured only the chymotrypsin-like activity of the protea-
some. Since the proteasome has three main types of proteo-
lytic activity, it is important to measure the caspase-like and
trypsin-like activities of the proteasome as these activities all
seem to be partly independent of each other [156–158].
7. Gene-Environment Interactions
After many years of intensive investigations for genetic risk
factors, no single genetic risk factor is used for risk assess-
ment. More recent genome-wide association (GWA) studies
further reveal novel genetic factors that contribute to disease
risk. However, the replication of many of these GWA studies
is still needed. Replication of some GWA studies showed
that some populations are more likely to be affected by
certain polymorphisms than other populations with the same
polymorphism. This is likely due to complex gene-environ-
ment interactions. Gene-environment relations are not well
understood, but recent evidence suggests that these relation-
ships may be more important than those previously known.
Most, if not all, diseases result from complex interactions
between an individual’s genetic makeup and environmental
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Figure 13: Sequences of human PSME4 and human PSMF1 subunits. Naturally occurring variants are highlighted with grey boxes.
Alternatively spliced regions are underlined. Amino acid residue numbers are shown on the right of each sequence. UniProt accession
numbers for PSME4 and PSMF1 are Q14997 and Q92530, respectively.
factors. People with different genetic variations sometimes
respond differently to the same environmental exposure. A
recent study using pooled data from 24 studies of the Breast
Cancer Association Consortium (34,793 invasive breast can-
cers and 41,099 controls) showed that the risk of breast cancer
associated with some common genetic variants varies with
environmental risk factors (such as alcohol consumption and
parity) [159].
8. Conclusions
In the last five years, genetic studies have significantly
increased our basic understanding of genes associated with
diseases. Several disease-associated and promising disease-
related candidate genes have been determined for diseases
ranging from cardiovascular diseases to immune diseases.
The known number of polymorphisms associated with dis-
ease and the number of diseases associated with polymor-
phisms are both likely to rise significantly over the next
decade. Numerous mutations and polymorphisms in other
proteasome genes (Table 1 and Figures 4, 5, 9, 10, 12, and
13) are already known, but the functional consequences of
these genetic variations are not known. Several mutations
in proteasome genes not associated with disease have been
found in diseased tissues, such as a somatic mutation in Rpt6
(PSMC5), R60Q, found in a colorectal cancer sample [39].
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Understanding whether or not these proteasome mutations
are important in disease development will require basic and
advanced research to determine how these mutations affect
proteasome function and how they affect the cell’s physiology.
Another question that still needs to be answered is what
factors contribute to some polymorphisms having a strong
association with diseases in one or a few ethnic groups but
not in other ethnic groups.
Studies involving tissues from patients have also
increased our understanding of the pathophysiology of
these diseases. While measurement of proteasome activity
in diseased tissues is important, measurement of purified
proteasome activities in these tissues is also needed to
determine if the effects of the polymorphism are directly due
to modulation of the proteasome or due to indirect effects.
It is possible that an amino acid change in a proteasome
subunit may cause altered proteasome activity by affecting its
interactionwith certain enzymes (e.g., preventing or reducing
phosphorylation at certain sites), or by affecting weak
associating proteins which alter proteasome activity. Another
factor that is not yet considered when determining the role of
polymorphisms on proteasome function is the large number
of posttranslational modifications that occur on proteasome
subunits [27, 160–162].The heterogeneity of posttranslational
modifications on proteasome subunits depends on many
factors which will vary significantly between individuals.
The most common posttranslational modification is possibly
phosphorylation, which can be removed by nonspecific phos-
phatases, allowing dephosphorylated, purified proteasomes
from normal and diseased tissues to be compared. Ideally,
expression of wild-type and mutant proteasome subunits
which are integrated into the intact 26S proteasome in a cell
culture system would allow the researchers to determine
if posttranslational modifications are major considerations
when defining the role of SNPs in proteasome functions.
Positive associations between a polymorphism and a
disease in case control association studies are often not repli-
cated in independent studies, as the design of many studies
lack the statistical power to properly detect any potential
association [163]. In general, larger population sizes are
needed for association studies.When large population studies
are unavailable, but enough “smaller” studies are available,
meta-analysis of GWA studies should be carried out. Better
collaboration between research groups and even countries is
needed to allow significantly larger population studies to be
conducted. These larger studies are critical to help unravel
the effects of environmental factors on disease related poly-
morphisms. Besides limited sample size, problems due to
false-positive results and publication bias are still a significant
problem [164].
The current standard of using phenotypic biomarkers for
clinical prognosis will continue for the foreseeable future
since these biomarkers integrate both genetic and nongenetic
factors. Nevertheless, in the near future it is likely that geno-
typing for specific SNPs will be useful in clinical diagnosis
and prognostic assessment of patients. SNP markers are
already being used in the diagnosis of a few diseases such
as Wilson disease [165]. An understanding of how the gene
polymorphisms affect proteins associated with disease will
likely lead to new drug targets and therapeutic approaches.
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